How DMPK should integrate with and influence projects in discovery and beyond
With Dr Richard Weaver, Senior Vice President – Preclinical Development
The chemical structure that has, by definition, been defined in a pre-clinical candidate may have flaws that could have been designed out if the DMPK scientist had been engaged earlier. Some of these recurring issues are: inadequate solubility, an unreasonable human dose projection, unacceptable human bioavailability, a non-existent safety margin, no real target engagement or lack of understanding of PK/PD.
Richard will give a tour of DMPK influence from Drug Discovery and beyond and highlight some of the pitfalls, misconceptions and advice in order to maximise success.